8-K: Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, Provides 2025 Guidance

Prothena announced its Q4 and full year 2024 financial results, highlighting R&D progress and providing financial guidance for 2025, including expected clinical milestones and cash usage.

Summary

• Prothena reported a net loss of $58.0 million for Q4 2024 and $122.3 million for the full year.
• This compares to a net loss of $67.5 million and $147.0 million for the same periods in 2023.
• Total revenue was $2.1 million for Q4 2024 and $135.2 million for the full year, compared to $0.3 million and $91.4 million in 2023.
• The company's R&D expenses were $50.2 million for Q4 and $222.5 million for the full year.
• G&A expenses totaled $16.8 million for Q4 and $67.2 million for the full year.
• Prothena's cash and restricted cash position at the end of 2024 was $472.2 million.
• The company expects net cash used in operating and investing activities for 2025 to be between $168 and $175 million.
• Prothena anticipates ending 2025 with approximately $301 million in cash.
• Topline results from the Phase 3 AFFIRM-AL clinical trial of birtamimab are expected in Q2 2025.
• Multiple clinical readouts for PRX012 are expected starting mid-2025 and continuing throughout the year.
• Bristol Myers Squibb initiated a Phase 2 clinical trial for BMS-986446 (formerly PRX005).

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While the company is still operating at a loss, there's progress in reducing the loss, increasing revenue, and advancing the clinical pipeline with key milestones expected in the near term. The partnerships with major pharmaceutical companies also contribute to a positive outlook.

Positives

• Net loss decreased compared to the previous year.
• Revenue increased significantly due to collaboration agreements.
• Multiple clinical trial milestones are expected in 2025.
• Bristol Myers Squibb licensed PRX019, providing an upfront payment and potential future revenue.
• Prothena has a strong cash position to fund its pipeline.

Negatives

• The company continues to operate at a net loss.
• Cash reserves are expected to decrease significantly in 2025 due to ongoing R&D expenses.

Risks

• Clinical trial results may not be favorable.
• The company's cash reserves are decreasing.
• Development and regulatory milestones may not be achieved.
• The company's estimated net loss for 2025 is between $197 and $205 million.

Future Outlook

Prothena expects 2025 to be a transformative year with multiple clinical milestones, including topline data from the Phase 3 AFFIRM-AL trial and multiple readouts from the Phase 1 ASCENT trials. The company anticipates ending 2025 with approximately $301 million in cash.

Management Comments

• Gene Kinney, Ph.D., President and Chief Executive Officer, stated that Prothena's R&D progress in 2024 was highlighted by continued advancements across the protein dysregulation portfolio.
• He also mentioned that 2025 is expected to be a transformative year for Prothena, driven by multiple clinical milestones from wholly-owned programs.
• Management is committed to developing novel medicines for neurodegenerative and rare peripheral amyloid diseases.

Industry Context

Prothena is focused on developing treatments for neurodegenerative and rare peripheral amyloid diseases, which are areas of significant unmet medical need. The company's pipeline includes both wholly-owned and partnered programs, reflecting a diversified approach to drug development. The collaboration with Bristol Myers Squibb and Roche highlights the industry's interest in Prothena's targets and technologies.

Comparison to Industry Standards

• Prothena's approach to targeting protein dysregulation in neurodegenerative diseases aligns with industry trends, as companies like Biogen, Eli Lilly, and Roche are also heavily invested in this area.
• The Phase 3 AFFIRM-AL trial for birtamimab is a key milestone, as AL amyloidosis treatments are limited, and a successful outcome could position Prothena as a leader in this space.
• The development of PRX012, a potential best-in-class antibody for Alzheimers disease, puts Prothena in competition with other companies developing amyloid-targeting therapies, such as Eisai and Biogen with Leqembi.
• The collaboration with Novo Nordisk on coramitug for ATTR amyloidosis with cardiomyopathy (ATTR-CM) places Prothena in a competitive landscape with companies like Alnylam and Ionis Pharmaceuticals, which have already launched RNAi-based therapies for ATTR amyloidosis.

Management Changes

Stakeholder Impact

• Shareholders: Potential for increased value if clinical trials are successful and products are commercialized.
• Employees: Continued employment and potential for growth within the company.
• Patients: Potential access to new treatments for neurodegenerative and rare peripheral amyloid diseases.
• Partners: Continued collaboration with Bristol Myers Squibb, Roche and Novo Nordisk.

Next Steps

• Report topline data from the Phase 3 AFFIRM-AL clinical trial in Q2 2025.
• Report multiple clinical readouts for PRX012 starting mid-2025 and continuing throughout the year.
• Continue Phase 1 clinical trial for PRX019.
• Update plans for Phase 1 clinical trial for PRX123 in 2025.

Key Dates